TITLE

Research Highlights

PUB. DATE
February 2011
SOURCE
Molecular Therapy;Feb2011, Vol. 19 Issue 2, p223
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
The article presents abstracts on stem cell research which include one about stem cell markers linked to poor prognosis in cancer patients, another on intestinal tissue created from stem cells, and another on protein therapy.
ACCESSION #
57749786

 

Related Articles

  • Prognostic factors and outcome of resected patients with gastrointestinal stromal tumors of small intestine. Fan, Rong; Zhong, Jie; Wang, Zhen-ting; Yu, Li-fen; Tang, Yong-hua; Hu, Wei-guo; Zhu, Yan-bo; Jin, Xiao-long // Medical Oncology;Dec2011, Vol. 28, p185 

    We document the clinical behavior of gastrointestinal stromal tumors (GISTs) of the small intestine and identify predictors for long-term disease-free survival (DFS) for small intestine GIST patients. From December 2001 to 2008, 114 consecutive patients with mesenchymal tumors involving the...

  • Colorectal cancer: A powerful model. Seton-Rogers, Sarah // Nature Reviews Cancer;Jan2013, Vol. 13 Issue 1, p8 

    The article presents a study aimed at investigating the mechanism of downstream WNT signaling on human colorectal cancer (CRC). It states that the study was conducted by performing the hyperproliferation of intestinal stem cells (ISCs). It mentions that the study also used mosaic analysis with a...

  • HMGA2 Inhibits Apoptosis through Interaction with ATR-CHK1 Signaling Complex in Human Cancer Cells. Natarajan, Suchitra; Hombach-Klonisch, Sabine; Dröge, Peter; Klonisch, Thomas // Neoplasia;Mar2013, Vol. 15 Issue 3, p263 

    The non-histone chromatin binding protein high mobility group AT-hook 2 (HMGA2) is expressed in stem cells and many cancer cells, including tumor initiating cells, but not translated in normal human somatic cells. The presence of HMGA2 is correlated with advanced neoplastic disease and poor...

  • ESP Abstracts 2013.  // Virchows Archiv;Aug2013, Vol. 463 Issue 2, p101 

    The article presents abstracts on medical topics which include the human epidermal growth factor receptor-2 (HER2) assessment in breast cancer, development of an in-situ immunohistochemistry method based on bright field technology, and identification of stem cells in triple negative breast cancer.

  • Small molecule antagonist of the bone morphogenetic protein type I receptors suppresses growth and expression of Id1 and Id3 in lung cancer cells expressing Oct4 or nestin. Langenfeld, Elaine; Deen, Malik; Zachariah, Emmanuel; Langenfeld, John // Molecular Cancer;2013, Vol. 12 Issue 1, p1 

    Background Bone morphogenetic proteins (BMP) are embryonic morphogens that are aberrantly expressed in lung cancer. BMPs mediate cell fate decisions and self-renewal of stem cells, through transcription regulation of inhibitor of differentiation protein/DNA binding proteins (Id1-3). Inhibition...

  • New strategies in controlling drug resistance in chronic myeloid leukemia. Frame, David // American Journal of Health-System Pharmacy;12/15/2007, Vol. 64 Issue 24, pS16 

    Purpose. Imatinib has been quite effective in maintaining patients with CML in the chronic phase (CP); however, some patients develop imatinib resistance. This review addresses the mechanisms underlying imatinib resistance and the strategies currently being used to overcome that resistance....

  • CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis. Sosulski, Amanda; Horn, Heiko; Zhang, Lihua; Coletti, Caroline; Vathipadiekal, Vinod; Castro, Cesar M.; Birrer, Michael J.; Nagano, Osamu; Saya, Hideyuki; Lage, Kasper; Donahoe, Patricia K.; Pépin, David // PLoS ONE;6/2/2016, Vol. 11 Issue 6, p1 

    CD44 is a transmembrane hyaluronic acid receptor gene that encodes over 100 different tissue-specific protein isoforms. The most ubiquitous, CD44 standard, has been used as a cancer stem cell marker in ovarian and other cancers. Expression of the epithelial CD44 variant containing exons v8-10...

  • Loss of enterocyte mass is accompanied by diminished turnover of enterocytes after myeloablative therapy in haematopoietic stem-cell transplant recipients. J. P. M. Derikx; N. M. A. Blijlevens; J. P. Donnelly; H. Fujii; T. Kanda; A. A. van Bijnen; E. Heineman; W. A. Buurman // Annals of Oncology;Feb2009, Vol. 20 Issue 2, p337 

    Background: Intestinal mucosal barrier injury (MBI), resulting from myeloablative conditioning for haematopoietic stem-cell transplantation (HSCT), is an important cause of morbidity. Despite its frequency, recognition presents a challenge, while the aetiology needs still to be unravelled. The...

  • Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Peng, S.; Maihle, N. J.; Huang, Y. // Oncogene;4/8/2010, Vol. 29 Issue 14, p2153 

    Lin28 and Oct4 are highly expressed in human embryonic stem (ES) cells and, along with two other stem cell marker proteins (Nanog and Sox2), together can convert human somatic cells to pluripotency. As an RNA-binding protein, Lin28 acts to stimulate the translation of a specific subset of mRNAs,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics